Project
Live Attenuated Rift Valley Fever Vaccine for Single Shot Application (LARISSA)
Wageningen Bioveterinary Research (WBVR) coordinates a public-private project aimed to develop a human Rift Valley fever vaccine.
Coalition for Epidemic Preparedness Innovations (CEPI)
The project is funded by CEPI, with support from the European Union’s Horizon 2020 programme. Up to USD 12.5 million is available for the project.
Coordinating role of WBVR
The project involves vaccine manufacturing, preclinical research, and a Phase 1 study to assess the safety, tolerability, and immunogenicity of a single-dose vaccine candidate against Rift Valley fever virus for use in humans. WBVR will lead a consortium of research, manufacturing, and clinical evaluation organisations to undertake the project.
A One Health approach
WBVR previously developed a live-attenuated experimental vaccine for animals that was shown to optimally combine efficacy with safety. In this CEPI project, similar technology will be used to develop a vaccine for human application.
Support from the EU Horizon 2020 programme
This investment is part of the third CEPI investment round, and is supported by the European Union Horizon 2020 research and innovation programme under grant agreement No. 857934.
Read more:
-
Novel Rift Valley fever vaccine dosed in Phase I human trial
- The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA... -
CEPI awards contract worth up to US$12.5 million to develop a human vaccine against Rift Valley fever
- Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI)...